ICU MEDICAL INC/DE
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $ICUI in the last 7 days.
ICU Medical Inc's (ICUI) VP and General Counsel Virginia Sanzone sold 4,856 shares at $168.69 each, totaling $819,000. She has sold 8,233 shares in the past year with no purchases. The company's stock has a P/E ratio of 140.92, higher than industry and historical averages. GuruFocus values the stock at $120.76, suggesting it is significantly overvalued.
ICU Medical's VP and General Counsel, Virginia Ruth Sanzone, sold 4,856 shares of common stock on September 3, 2026, under a Rule 10b5-1 trading plan adopted in June 2026. The sales occurred in four transactions at weighted average prices ranging from $167.67 to $171.52 per share, totaling approximately $819,000.
Sanzone Virginia Ruth (VP, General Counsel) sold 4,856 shares of ICU MEDICAL INC/DE (ICUI) at an average of $168.69 ($167.67–$171.52, $0.82M total) across 4 trades on 2026-09-03 under a Rule 10b5-1 trading plan.
Recent ICUI coverage spans insider activity, financial news and earnings.
In the last 30 days, ICUI insiders filed 9 SEC Form 4 transactions — no purchases and 9 sales ($3.5M). The most active reporter was Bonnell Brian Michael, Chief Financial Officer, with 5 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The insider sale may signal management's lack of confidence, but the amount is modest relative to market cap.
The insider sale represents a modest reduction of holdings, unlikely to move the stock significantly.
Insider sale may signal personal liquidity need or lack of confidence, but size is modest.
The insider sale may signal reduced confidence from the CFO, potentially pressuring the stock short-term.
The insider sale may signal CFO confidence level and could pressure the stock short-term.
AlphAI scores every news story that mentions ICUI with an AI model for sentiment and relevance, and aggregates insider trades from ICU MEDICAL INC/DE's SEC EDGAR Form 4 filings. Figures refresh continuously.
ICU Medical Inc's (ICUI) VP and General Counsel Virginia Sanzone sold 4,856 shares at $168.69 each, totaling $819,000. She has sold 8,233 shares in the past year with no purchases. The company's stock has a P/E ratio of 140.92, higher than industry and historical averages. GuruFocus values the stock at $120.76, suggesting it is significantly overvalued.
2 min readICU Medical's VP and General Counsel, Virginia Ruth Sanzone, sold 4,856 shares of common stock on September 3, 2026, under a Rule 10b5-1 trading plan adopted in June 2026. The sales occurred in four transactions at weighted average prices ranging from $167.67 to $171.52 per share, totaling approximately $819,000.
1 min readSanzone Virginia Ruth (VP, General Counsel) sold 4,856 shares of ICU MEDICAL INC/DE (ICUI) at an average of $168.69 ($167.67–$171.52, $0.82M total) across 4 trades on 2026-09-03 under a Rule 10b5-1 trading plan.
1 min readBonnell Brian Michael (Chief Financial Officer) sold 6,381 shares of ICU MEDICAL INC/DE (ICUI) at $175.00 ($1.12M total) on 2026-09-01 under a Rule 10b5-1 trading plan.
1 min readBonnell Brian Michael (Chief Financial Officer) sold 9,307 shares of ICU MEDICAL INC/DE (ICUI) at an average of $172.79 ($171.05–$173.91, $1.61M total) across 4 trades on 2026-08-31 under a Rule 10b5-1 trading plan.
1 min readS&P Global Ratings upgraded ICU Medical Inc. to 'BB' from 'BB-', citing improved credit metrics and strong operating performance. The company's adjusted leverage decreased to 3.1x in Q2 2026, with free operating cash flow exceeding expectations. ICU Medical used proceeds from asset sales and cash flow to reduce debt. S&P projects mid-single-digit revenue growth and margin improvement through 2027, with a stable outlook based on expected debt and cash flow metrics.
2 min readICU Medical (ICUI) reported Q2 2026 revenue of $551.7M, up 1% reported and 6% organic excluding IV Solutions divestiture and currency. Infusion Systems revenue was $189.0M (+12% organic), Consumables $289.3M (+5% organic). Adjusted EBITDA was $110.0M (+10%). Full-year guidance raised to $415M-$435M EBITDA and $8.60-$9.00 EPS.
7 min readWoolson Daniel (VP, GM-Infusion Capital) sold 5,417 shares of ICU MEDICAL INC/DE (ICUI) at $181.33 ($0.98M total) on 2026-08-13.
2 min readICU Medical (ICUI) reported Q2 strength in Infusion Systems and Consumables, citing North America growth, record pump and consumables quarters, and margin gains from IT integration and facility consolidation. CEO Vivek Jain said growth came from competitive wins and earlier installations, with organic Infusion Systems growth at or above 6%. Tariffs and currency headwinds were partly offset by execution. Shares were $179.30.
5 min readSousa Ben (Chief Information Officer) sold 2,250 shares of ICU MEDICAL INC/DE (ICUI) at $178.32 ($0.40M total) on 2026-08-12.
2 min read
